CGEM

7.50

0.92% -0.07

Pre-mercato: 7.35 -0.15 -2.00%

Cullinan Therapeutics Inc (CGEM)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$7.57

Aprire:

$7.55

Volume 24 ore:

613.61K

Relative Volume:

1.35

Capitalizzazione di mercato:

$438.85M

Reddito:

Utile/perdita netta:

$-153.16M

Rapporto P/E:

-2.0325

EPS:

-3.69

Flusso di cassa netto:

$-134.48M

1 W Prestazione:

-9.64%

1M Prestazione:

-11.66%

6M Prestazione:

-55.25%

1 anno Prestazione:

-57.51%

Intervallo 1D:

$7.2698

$7.55

Intervallo di 1 settimana:

$7.2698

$8.495

Portata 52W:

$7.2698

$30.19

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Nome

Cullinan Therapeutics Inc

Settore

Healthcare (1165)

Industria

Biotechnology (681)

Telefono

617-410-4650

Indirizzo

ONE MAIN STREET, CAMBRIDGE

Dipendente

111

Cinguettio

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

CGEM's Discussions on Twitter

Confronta CGEM con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CGEM Cullinan Therapeutics Inc	7.50	438.85M	0	-153.16M	-134.48M	-3.69
VRTX Vertex Pharmaceuticals Inc	484.74	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	617.00	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	567.09	34.59B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	255.76	33.10B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	271.04	29.15B	3.81B	-644.79M	-669.77M	-6.24

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-10-24	Iniziato	UBS	Buy
2024-05-01	Iniziato	Stifel	Buy
2024-04-15	Iniziato	William Blair	Outperform
2024-02-15	Iniziato	Wedbush	Outperform
2023-06-15	Iniziato	TD Cowen	Outperform
2022-11-21	Iniziato	BTIG Research	Buy
2021-04-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2021-02-02	Iniziato	Evercore ISI	Outperform
2021-02-02	Iniziato	Morgan Stanley	Equal-Weight
2021-02-02	Iniziato	SVB Leerink	Outperform
2021-02-01	Iniziato	H.C. Wainwright	Buy

Mostra tutto

Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie

Mar 30, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Swiss National Bank - Defense World

Mar 30, 2025

Mar 26, 2025

Charles Schwab Investment Management Inc. Has $5.25 Million Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Mar 26, 2025

Mar 24, 2025

20,273 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Purchased by Connor Clark & Lunn Investment Management Ltd. - Defense World

Mar 24, 2025

Mar 16, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 2.1% – Time to Sell? - Defense World

Mar 16, 2025

Mar 12, 2025

EGFR Non-Small Cell Lung Cancer Clinical and Non-Clinical - openPR

Mar 12, 2025

Mar 09, 2025

Morgan Stanley Reaffirms Overweight Rating for Cullinan Therapeutics (NASDAQ:CGEM) - Defense World

Mar 09, 2025

Mar 08, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Recommendation of “Buy” from Analysts - Defense World

Mar 08, 2025

Mar 07, 2025

Cullinan Therapeutics: Promising Pipeline and Upcoming Catalysts Justify Buy Rating - TipRanks

Mar 07, 2025

Rhumbline Advisers Raises Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Mar 07, 2025

Mar 06, 2025

New York State Common Retirement Fund Buys 3,200 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Mar 06, 2025

Cullinan Therapeutics (CGEM) to Release Quarterly Earnings on Thursday - Defense World

Mar 06, 2025

Mar 04, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Given "Buy" Rating at HC Wainwright - MarketBeat

Mar 04, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Announces Earnings Results - MarketBeat

Mar 04, 2025

Mar 03, 2025

Q1 Earnings Estimate for CGEM Issued By William Blair - Defense World

Mar 03, 2025

Cullinan Therapeutics’ (CGEM) “Buy” Rating Reiterated at HC Wainwright - Defense World

Mar 03, 2025

Mar 01, 2025